M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase
- PMID: 14502240
- DOI: 10.1038/sj.cdd.4401285
M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase
Abstract
Multinucleated bone-resorbing osteoclasts (Ocl) are cells of hematopoietic origin that play a major role in osteoporosis pathophysiology. Ocl survival and activity require M-CSF and RANK ligand (RANKL). M-CSF signals to Akt, while RANKL, like TNFalpha, activates NF-kappaB. We show here that although these are separate pathways in the Ocl, signaling of all three cytokines converges on mammalian target of rapamycin (mTOR) as part of their antiapoptotic action. Accordingly, rapamycin blocks M-CSF- and RANKL-dependent Ocl survival inducing apoptosis, and suppresses in vitro bone resorption proportional to the reduction in Ocl number. The cytokine signaling intermediates for mTOR/ribosomal protein S6 kinase (S6K) activation include phosphatidylinositol-3 kinase, Akt, Erks and geranylgeranylated proteins. Inhibitors of these intermediates suppress cytokine activation of S6K and induce Ocl apoptosis. mTOR regulates protein translation acting via S6K, 4E-BP1 and S6. We find that inhibition of translation by other mechanisms also induces Ocl apoptosis, demonstrating that Ocl survival is highly sensitive to continuous de novo protein synthesis. This study thus identifies mTOR/S6K as an essential signaling pathway engaged in the stimulation of cell survival in osteoclasts.
Similar articles
-
Activin A stimulates IkappaB-alpha/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors.J Cell Biochem. 2003 Sep 1;90(1):59-67. doi: 10.1002/jcb.10613. J Cell Biochem. 2003. PMID: 12938156
-
Decoy receptor 3 (DcR3) induces osteoclast formation from monocyte/macrophage lineage precursor cells.Cell Death Differ. 2004 Jul;11 Suppl 1:S97-107. doi: 10.1038/sj.cdd.4401403. Cell Death Differ. 2004. PMID: 15002040
-
Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction.J Exp Med. 2000 Jan 17;191(2):275-86. doi: 10.1084/jem.191.2.275. J Exp Med. 2000. PMID: 10637272 Free PMC article.
-
[Inflammation and osteoclasts].Nihon Rinsho Meneki Gakkai Kaishi. 2017;40(5):367-376. doi: 10.2177/jsci.40.367. Nihon Rinsho Meneki Gakkai Kaishi. 2017. PMID: 29238019 Review. Japanese.
-
Canonical and non-canonical pathways of osteoclast formation.Histol Histopathol. 2009 Mar;24(3):337-46. doi: 10.14670/HH-24.337. Histol Histopathol. 2009. PMID: 19130404 Review.
Cited by
-
New Insights into the Pro-Inflammatory and Osteoclastogenic Profile of Circulating Monocytes in Osteoarthritis Patients.Int J Mol Sci. 2024 Jan 30;25(3):1710. doi: 10.3390/ijms25031710. Int J Mol Sci. 2024. PMID: 38338988 Free PMC article.
-
The mTOR signalling pathway in human cancer.Int J Mol Sci. 2012;13(2):1886-1918. doi: 10.3390/ijms13021886. Epub 2012 Feb 10. Int J Mol Sci. 2012. PMID: 22408430 Free PMC article. Review.
-
Role of Altered Metabolic Microenvironment in Osteolytic Metastasis.Front Cell Dev Biol. 2020 Jun 5;8:435. doi: 10.3389/fcell.2020.00435. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 32582711 Free PMC article. Review.
-
Osteocyte TSC1 promotes sclerostin secretion to restrain osteogenesis in mice.Open Biol. 2019 May 31;9(5):180262. doi: 10.1098/rsob.180262. Open Biol. 2019. PMID: 31088250 Free PMC article.
-
RANKL increases the level of Mcl-1 in osteoclasts and reduces bisphosphonate-induced osteoclast apoptosis in vitro.Arthritis Res Ther. 2009;11(2):R58. doi: 10.1186/ar2681. Epub 2009 Apr 30. Arthritis Res Ther. 2009. PMID: 19405951 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
